Nathwani et al. described that peripheral-vein infusion of a modified AAV carrying a codon-optimized human factor IX (F9) can induce the F9 transgene expression to improve the bleeding phenotype in patients with hemophilia B [113]. The gene discussed is F9; the disease is hemophilia B.